ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE

July 27, 2001

Forteo (teriparatid injection, rDNA origin)  NDA 21-318

Briefing Information

Eli Lilly and Company   pdf

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

FDA Backgrounder   htm